nicoelnino-shutterstock-com-lsipr-

NicoElNino / Shutterstock.com

17 March 2016AmericasChristopher Jagoe and James McConnell

The role of healthy sales in IPR

The commercial success of a patented life sciences invention generally fails to persuade the Patent Trial and Appeal Board (PTAB) that it is evidence of non-obviousness in inter partes review (IPR) trials.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

UKIPO rejects Boehringer’s SPC for horse inhaler

Bayer, Orion take on Indian generic over $117bn drug

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?

BMS faces fresh lawsuit over alleged cancer drug monopoly